文献速递骨显像与常规 SPECT放射性药物与辐射防护

全膝关节置换术后疼痛中骨SPECT/CT的成本效益分析

Cost-Effectiveness of Bone SPECT/CT in Painful Total Knee Arthroplasty.
PubMed 文献 · J Nucl Med · 2018-03-30

本研究基于Excel模拟模型,从支付方视角比较骨SPECT/CT与CT或金属伪影减少序列(MARS)-MRI对全膝关节置换术后复发中重度疼痛的诊断评估经济价值。每1000例患者中,骨SPECT/CT较CT三年节省1,867,695美元,较MARS-MRI节省1,723,435美元,增量质量调整生命年分别为39.7和41.0,可视为成本节约且占优的策略。

要点

  • 每1000例TKA患者,骨SPECT/CT较CT三年节省1,867,695美元(每患者每年622.6美元)。
  • 每1000例TKA患者,骨SPECT/CT较MARS-MRI三年节省1,723,435美元(每患者每年574.5美元)。
  • 骨SPECT/CT相较CT和MARS-MRI的增量QALY分别为39.7和41.0,为成本节约且占优策略。

核心结论

  • 骨SPECT/CT与CT或MARS-MRI扫描相比,对全膝关节置换术后复发和持续性膝痛患者可能是高度成本节约且占优的影像干预。

研究设计与样本

  • 基于Excel的模拟模型,从支付方视角比较骨SPECT/CT与CT或MARS-MRI。
  • 临床终点及相应成本数据(2017年美元)通过已发表文献的最佳证据回顾获得。
  • 研究进行汇总并按样本量加权参数,执行成本-效用分析估算增量成本每质量调整生命年,并进行单向(±25%)敏感性分析评估模型稳健性。

主要发现

  • 每1000例TKA患者,诊断性骨SPECT/CT较CT三年节省高达1,867,695美元(每患者每年622.6美元)。
  • 每1000例TKA患者,骨SPECT/CT较MARS-MRI三年节省1,723,435美元(每患者每年574.5美元)。
  • 骨SPECT/CT相较CT和MARS-MRI的增量质量调整生命年分别为39.7和41.0。

局限性

  • 模型受限于仍然稀疏的文献数据。
  • 模型对影像相关的灵敏度/特异度最为敏感。
  • 模型在手术/非手术疼痛原因的不同患病率下证明稳健。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to quantify the economic value of bone SPECT/CT versus CT or metal artifact reduction sequence (MARS)-MRI for the diagnostic assessment of recurrent moderate-to-severe pain after total knee arthroplasty (TKA). Methods: An Excel-based simulation model was developed to compare bone SPECT/CT versus CT or MARS-MRI from a payer perspective. Clinical endpoints (diagnosis-delayed or otherwise, and the subsequent treatment and complications) and their corresponding cost data (2017 U.S. dollars) were obtained by performing a best evidence review of the published literature. Studies were pooled and parameters weighted by sample size. A cost-utility analysis was performed estimating the incremental cost per quality-adjusted life years gained between bone SPECT/CT and the comparative scans. One-way (±25%) sensitivity analysis was performed to gauge the model robustness. Results: For every 1,000 TKA patients, diagnostic bone SPECT/CT was expected to lead to 3-y cost savings up to $1,867,695 versus CT (or $622.6 per patient per year) and $1,723,435 versus MARS-MRI (or $574.5 per patient per year) for a payer. With corresponding incremental quality-adjusted life years gains of 39.7 and 41.0 against CT and MARS-MRI, SPECT/CT can be considered as a cost-saving and dominant strategy in the workup of persistent/recurrent pain in TKA patients. The model was limited by the still sparse literature data, was most sensitive to imaging-related sensitivity/specificity, but proved robust for varying prevalence of surgical/nonsurgical causes of pain. Conclusion: Bone SPECT/CT is a potentially highly cost-saving and dominant imaging intervention versus CT or MARS-MR scanning in patients with recurrent and persistent knee pain after TKA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Van den Wyngaert T, Palli SR, Imhoff RJ, et al. Cost-Effectiveness of Bone SPECT/CT in Painful Total Knee Arthroplasty. J Nucl Med. 2018. PMID: 29602816. doi:10.2967/jnumed.117.205567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。